ENSC Ensysce Biosciences, Inc.

NASDAQ
$0.46

Ensysce Biosciences, Inc. (ENSC) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +34.4% since its last earnings release on August 13, 2026.

Ensysce Biosciences Beat Consensus Estimates
Thursday, August 13, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($0.19)
Rev est $5.3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.40

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ensysce Biosciences, Inc.

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology